Jeff S Healey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7763355/publications.pdf

Version: 2024-02-01

20759 12910 18,926 284 60 131 citations h-index g-index papers 292 292 292 14758 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Subclinical Atrial Fibrillation and the Risk of Stroke. New England Journal of Medicine, 2012, 366, 120-129.	13.9	1,751
2	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. Circulation, 2011, 123, 2363-2372.	1.6	1,035
3	Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Journal of the American College of Cardiology, 2005, 45, 1832-1839.	1.2	774
4	Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. New England Journal of Medicine, 2016, 375, 111-121.	13.9	616
5	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. Circulation, 2014, 129, 2094-2099.	1.6	579
6	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. Circulation, 2012, 126, 343-348.	1.6	494
7	Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation. New England Journal of Medicine, 2013, 368, 2084-2093.	13.9	482
8	Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. Canadian Journal of Cardiology, 2012, 28, 125-136.	0.8	461
9	Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. American Heart Journal, 2005, 150, 288-293.	1.2	436
10	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. European Heart Journal, 2017, 38, 1339-1344.	1.0	428
11	Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. Journal of the American College of Cardiology, 2007, 50, 2156-2161.	1.2	422
12	2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2014, 30, 1114-1130.	0.8	382
13	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. Circulation, 2014, 129, 1568-1576.	1.6	324
14	Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. New England Journal of Medicine, 2021, 384, 2081-2091.	13.9	321
15	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	0.8	313
16	Cardioembolic Stroke. Circulation Research, 2017, 120, 514-526.	2.0	273
17	Perioperative Atrial Fibrillation and the Long-term Risk of Ischemic Stroke. JAMA - Journal of the American Medical Association, 2014, 312, 616.	3.8	266
18	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. European Heart Journal, 2015, 36, 281-288.	1.0	253

#	Article	IF	Citations
19	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1170-1185.	0.8	243
20	Irbesartan in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 364, 928-938.	13.9	220
21	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet, The, 2016, 388, 1161-1169.	6.3	216
22	Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). Lancet, The, 2015, 385, 785-791.	6.3	214
23	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Thrombosis and Haemostasis, 2015, 113, 625-632.	1.8	201
24	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm, 2016, 13, e50-e86.	0.3	197
25	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2018, 34, 1371-1392.	0.8	195
26	Subclinical Atrial Fibrillation in Older Patients. Circulation, 2017, 136, 1276-1283.	1.6	194
27	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación CardÃaca v ElectrofisiologÃa (SOLEACE). Europace. 2017. 19. 1556-1578.	0.7	186
28	Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. Stroke, 2008, 39, 1482-1486.	1.0	177
29	Atrial Premature Beats Predict Atrial Fibrillation in Cryptogenic Stroke. Stroke, 2015, 46, 936-941.	1.0	157
30	Cardiac Resynchronization Therapy in Patients With Permanent Atrial Fibrillation. Circulation: Heart Failure, 2012, 5, 566-570.	1.6	155
31	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. Journal of the American College of Cardiology, 2016, 67, 1300-1308.	1.2	154
32	Deviceâ€Related Infection Among Patients With Pacemakers and Implantable Defibrillators: Incidence, Risk Factors, and Consequences. Journal of Cardiovascular Electrophysiology, 2010, 21, 786-790.	0.8	153
33	Atrioventricular Block as the Initial Manifestation of Cardiac Sarcoidosis in Middleâ€Aged Adults. Journal of Cardiovascular Electrophysiology, 2014, 25, 875-881.	0.8	150
34	Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation. JAMA Neurology, 2019, 76, 764.	4.5	147
35	Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock. JAMA - Journal of the American Medical Association, 2018, 319, 1889.	3.8	145
36	Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: An analysis from ASSERT. Heart Rhythm, 2012, 9, 1241-1246.	0.3	141

#	Article	IF	Citations
37	Recommendations for the Use of Genetic Testing in the Clinical Evaluation of Inherited Cardiac Arrhythmias Associated with Sudden Cardiac Death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Paper. Canadian Journal of Cardiology, 2011, 27, 232-245.	0.8	139
38	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2016, 18, 159-183.	0.7	135
39	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). European Heart Journal, 2018, 39, 3973-3979.	1.0	131
40	Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. Annals of Cardiothoracic Surgery, 2014, 3, 45-54.	0.6	125
41	ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). American Heart Journal, 2006, 152, 442-447.	1.2	117
42	An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis. European Heart Journal, 2018, 39, 3932-3944.	1.0	114
43	Blockade of the renin–angiotensin–aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: A systematic review and meta analysis of randomized controlled trials. International Journal of Cardiology, 2013, 165, 17-24.	0.8	106
44	Screening for Atrial Fibrillation in the Older Population. JAMA Cardiology, 2021, 6, 558.	3.0	101
45	Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Canadian Journal of Cardiology, 2020, 36, 948-951.	0.8	100
46	Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nature Reviews Cardiology, 2017, 14, 701-714.	6.1	98
47	Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. American Heart Journal, 2007, 154, 448-453.	1.2	97
48	Are Elderly Patients at Increased Risk of Complications Following Pacemaker Implantation? A Metaâ€Analysis of Randomized Trials. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 131-134.	0.5	96
49	Left Atrial Appendage Occlusion Study II (LAAOS II). Canadian Journal of Cardiology, 2013, 29, 1443-1447.	0.8	95
50	Postoperative Lowâ€Molecularâ€Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 378-382.	0.5	92
51	Progression of Device-Detected Subclinical Atrial Fibrillation and the RiskÂof Heart Failure. Journal of the American College of Cardiology, 2018, 71, 2603-2611.	1.2	91
52	Identifying Patients With Atrial Fibrillation in Administrative Data. Canadian Journal of Cardiology, 2016, 32, 1561-1565.	0.8	90
53	Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. PLoS Medicine, 2019, 16, e1002903.	3.9	90
54	Human Study of Biatrial Electrical Coupling. Circulation, 2004, 110, 2083-2089.	1.6	87

#	Article	IF	Citations
55	Pacemaker-Detected Atrial Fibrillation in Patients WithÂPacemakers: Prevalence, Predictors, and Current UseÂof Oral Anticoagulation. Canadian Journal of Cardiology, 2013, 29, 224-228.	0.8	83
56	Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. International Journal of Cardiology, 2015, 196, 127-131.	0.8	74
57	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Etiology and Initial Investigations. Canadian Journal of Cardiology, 2011, 27, 31-37.	0.8	65
58	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. Circulation, 2022, 145, 392-409.	1.6	65
59	Left Atrial Appendage Occlusion Does Not Eliminate the Need for Warfarin. Circulation, 2009, 120, 1927-1932.	1.6	63
60	A Systematic Review on the Progression of Paroxysmal to Persistent Atrial Fibrillation. JACC: Clinical Electrophysiology, 2015, 1, 105-115.	1.3	63
61	Questioning patient engagement: research scientists' perceptions of the challenges of patient engagement in a cardiovascular research network. Patient Preference and Adherence, 2017, Volume 11, 1573-1583.	0.8	63
62	The Phenotypic Spectrum of a MutationÂHotspot Responsible for theÂShort QT Syndrome. JACC: Clinical Electrophysiology, 2017, 3, 727-743.	1.3	58
63	Canadian Cardiovascular Society/Canadian Anesthesiologists' Society/Canadian Heart Rhythm Society Joint Position Statement on the Perioperative Management of Patients With Implanted Pacemakers, Defibrillators, and Neurostimulating Devices. Canadian Journal of Cardiology, 2012, 28, 141-151.	0.8	56
64	Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices. Journal of Cardiovascular Electrophysiology, 2013, 24, 381-387.	0.8	55
65	Atrial overdrive pacing to prevent atrial fibrillation: Insights from ASSERT. Heart Rhythm, 2012, 9, 1667-1673.	0.3	54
66	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation, 2022, 145, 1693-1704.	1.6	54
67	Evaluation of Genes Encoding for the Transient Outward Current (Ito) Identifies the <i>KCND2</i> Gene as a Cause of J-Wave Syndrome Associated With Sudden Cardiac Death. Circulation: Cardiovascular Genetics, 2014, 7, 782-789.	5.1	53
68	Predictors of early and late stroke following cardiac surgery. Cmaj, 2014, 186, 905-911.	0.9	52
69	Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy. Heart Rhythm, 2015, 12, 2148-2154.	0.3	52
70	The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial. American Heart Journal, 2018, 197, 124-132.	1.2	50
71	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. European Heart Journal, 2020, 41, 1132-1140.	1.0	50
72	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007437.	2.1	49

#	Article	IF	CITATIONS
73	Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace, 2018, 20, 1442-1450.	0.7	47
74	Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. Current Opinion in Cardiology, 2005, 20, 31-7.	0.8	47
75	Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure. Stroke, 2015, 46, 667-672.	1.0	46
76	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of <i>CASQ2 < /i>-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2020, 142, 932-947.</i>	1.6	44
77	Stroke Prevention in Atrial Fibrillation. Circulation, 2020, 142, 2371-2388.	1.6	44
78	Prevalence and Risk Factors for Cervical and Lumbar Spondylosis in Interventional Electrophysiologists. Journal of Cardiovascular Electrophysiology, 2011, 22, 957-960.	0.8	43
79	The 2014 Atrial Fibrillation Guidelines Companion: AÂPractical Approach to the Use of the Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2015, 31, 1207-1218.	0.8	43
80	Research Priorities in Atrial Fibrillation Screening. Circulation, 2021, 143, 372-388.	1.6	42
81	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	3.9	42
82	Predictors of Atrioâ€Ventricular Conduction Disease, Longâ€Term Outcomes in Patients with Myotonic Dystrophy Types I and II. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 1262-1269.	0.5	41
83	The Burden of Atrial Fibrillation on the Hospital Sector in Canada. Canadian Journal of Cardiology, 2013, 29, 229-235.	0.8	41
84	Impact of Cardiac Implantable Electronic Device Infection. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008280.	2.1	41
85	Atrial fibrillation is associated with increased mortality: causation or association?. European Heart Journal, 2013, 34, 1027-1030.	1.0	40
86	The Prognostic Significance of Bundle Branch Block in Highâ€Risk Chronic Stable Vascular Disease Patients: A Report from the HOPE Trial. Journal of Cardiovascular Electrophysiology, 2009, 20, 781-787.	0.8	39
87	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Global Heart, 2021, 16, 41.	0.9	39
88	Canadian Registry of ICD Implant Testing Procedures (CREDIT): Current Practice, Risks, and Costs of Intraoperative Defibrillation Testing. Journal of Cardiovascular Electrophysiology, 2010, 21, 177-182.	0.8	38
89	High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. Open Heart, 2016, 3, e000515.	0.9	38
90	Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices and apps: A survey of health care professionals by AF-SCREEN international collaboration. European Journal of Internal Medicine, 2020, 82, 97-104.	1.0	38

#	Article	IF	CITATIONS
91	Sodiumâ€Glucose Coâ€Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e022222.	1.6	38
92	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. Europace, 2021, 23, 329-344.	0.7	38
93	Atrial fibrillation detected initially during acute medical illness: A systematic review. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 130-141.	0.4	37
94	Metaâ€Analysis of Continuous Oral Anticoagulants Versus Heparin Bridging in Patients Undergoing CIED Surgery: Reappraisal after the BRUISE Study. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 417-423.	0.5	36
95	Importance of genetic testing in unexplained cardiac arrest. European Heart Journal, 2022, 43, 3071-3081.	1.0	36
96	The management of patients with carotid sinus syndrome: is pacing the answer?. Clinical Autonomic Research, 2004, 14, i80-i86.	1.4	35
97	A Randomizedâ€Controlled Pilot Study Comparing ICD Implantation with and Without Intraoperative Defibrillation Testing in Patients with Heart Failure and Severe Left Ventricular Dysfunction: A Substudy of the RAFT Trial. Journal of Cardiovascular Electrophysiology, 2012, 23, 1313-1316.	0.8	35
98	Managing Novel Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Device Surgery: Canadian Survey. Canadian Journal of Cardiology, 2014, 30, 231-236.	0.8	35
99	Prevalence of Left Atrial Thrombus inÂAnticoagulated Patients With AtrialÂFibrillation. Journal of the American College of Cardiology, 2021, 77, 2875-2886.	1.2	35
100	2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverterâ€defibrillator programming and testing. Journal of Arrhythmia, 2016, 32, 1-28.	0.5	34
101	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. American Heart Journal, 2016, 173, 102-107.	1.2	34
102	How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Annals of Internal Medicine, 2015, 163, 382-385.	2.0	33
103	Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. Canadian Journal of Cardiology, 2019, 35, 389-395.	0.8	33
104	The rationale and design of the Shockless IMPLant Evaluation (SIMPLE) trial: A randomized, controlled trial of defibrillation testing at the time of defibrillator implantation. American Heart Journal, 2012, 164, 146-152.	1.2	32
105	Evolution of clinical diagnosis in patients presenting with unexplained cardiac arrest or syncope due to polymorphic ventricular tachycardia. Heart Rhythm, 2014, 11, 274-281.	0.3	32
106	Screening for Atrial Fibrillation Using a Mobile, Single-Lead Electrocardiogram in Canadian Primary Care Clinics. Canadian Journal of Cardiology, 2019, 35, 840-845.	0.8	31
107	Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. European Journal of Internal Medicine, 2021, 92, 100-106.	1.0	31
108	Relevance of Electrical Remodeling in Human Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 626-631.	2.1	30

#	Article	IF	Citations
109	Improvement of apparently fixed pulmonary hypertension with cardiac resynchronization therapy. Journal of Heart and Lung Transplantation, 2004, 23, 650-652.	0.3	29
110	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. Thrombosis Research, 2016, 139, 77-81.	0.8	29
111	Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis. Canadian Journal of Cardiology, 2013, 29, 1203-1210.	0.8	28
112	Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. Heart Rhythm, 2014, 11, 2156-2162.	0.3	28
113	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation. JAMA Cardiology, 2017, 2, 324.	3.0	28
114	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. Canadian Journal of Cardiology, 2019, 35, 1069-1077.	0.8	27
115	Atrial Cardiopathy in the Absence of Atrial Fibrillation Increases Risk of Ischemic Stroke, Incident Atrial Fibrillation, and Mortality and Improves Stroke Risk Prediction. Journal of the American Heart Association, 2020, 9, e013227.	1.6	27
116	Implantable cardioverter-defibrillator shock prevention does not reduce mortality: A systemic review. Heart Rhythm, 2012, 9, 2068-2074.	0.3	26
117	Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. Europace, 2017, 19, euw221.	0.7	26
118	Mexiletine or catheter ablation after amiodarone failure in the VANISH trial. Journal of Cardiovascular Electrophysiology, 2018, 29, 603-608.	0.8	26
119	Atrial fibrillation occurring transiently with stress. Current Opinion in Cardiology, 2018, 33, 58-65.	0.8	26
120	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007545.	2.1	25
121	Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 938-943.	1.0	25
122	Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation. Circulation, 2020, 141, 482-492.	1.6	25
123	Management of Anticoagulation Around Pacemaker and Defibrillator Surgery. Circulation, 2014, 129, 2062-2065.	1.6	24
124	North American Thrombosis Forum, AF Action Initiative Consensus Document. American Journal of Medicine, 2016, 129, S1-S29.	0.6	24
125	Cardiac resynchronization is pro-arrhythmic in the absence of reverse ventricular remodelling: a systematic review and meta-analysis. Cardiovascular Research, 2018, 114, 1435-1444.	1.8	23
126	Challenge and Impact of Quinidine Access in Sudden Death Syndromes. JACC: Clinical Electrophysiology, 2019, 5, 376-382.	1.3	23

#	Article	IF	Citations
127	Atrial fibrillation and stroke: how much atrial fibrillation is enough to cause a stroke?. Current Opinion in Neurology, 2020, 33, 17-23.	1.8	23
128	Atrial overdrive pacing in sleep apnoea: a meta-analysis. Europace, 2009, 11, 1037-1040.	0.7	22
129	VDD vs DDD Pacemakers: A Meta-analysis. Canadian Journal of Cardiology, 2014, 30, 1385-1391.	0.8	22
130	Bucindolol for the Maintenance of SinusÂRhythm in a Genotype-Defined HFÂPopulation. JACC: Heart Failure, 2019, 7, 586-598.	1.9	22
131	Left Atrial Appendage Occlusion Debate Revisited. Circulation, 2015, 131, 756-761.	1.6	21
132	Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. CMAJ Open, 2017, 5, E653-E661.	1.1	21
133	Colchicine for Prevention of Perioperative Atrial Fibrillation in patients undergoing lung resection surgery: a pilot randomized controlled study. European Journal of Cardio-thoracic Surgery, 2018, 53, 945-951.	0.6	21
134	Prevalence of risk factors for atrial fibrillation and stroke among 1210 patients with sleep disordered breathing. International Journal of Cardiology, 2014, 174, 73-76.	0.8	20
135	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. Europace, 2017, 19, euw116.	0.7	20
136	Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis. Europace, 2019, 21, 856-863.	0.7	20
137	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. American Heart Journal, 2021, 234, 90-100.	1.2	20
138	Strokeâ€prevention strategies in North American patients with atrial fibrillation: The GLORIAâ€AF registry program. Clinical Cardiology, 2018, 41, 744-751.	0.7	19
139	Rationale and design of the randomized prospective ATLAS study: Avoid Transvenous Leads in Appropriate Subjects. American Heart Journal, 2019, 207, 1-9.	1.2	19
140	Cost-effectiveness of physiologic pacing: Results of the Canadian Health Economic Assessment of Physiologic Pacing. Heart Rhythm, 2005, 2, 270-275.	0.3	18
141	Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy. Open Cardiovascular Medicine Journal, 2014, 8, 113-120.	0.6	18
142	Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older?. Canadian Journal of Cardiology, 2018, 34, 1522-1525.	0.8	17
143	Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis. Europace, 2019, 21, 1159-1166.	0.7	17
144	Short-term and Long-term Risk of Stroke in Patients With Perioperative Atrial Fibrillation After Cardiac Surgery: Systematic Review and Meta-analysis. CJC Open, 2022, 4, 85-96.	0.7	17

#	Article	IF	Citations
145	Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? A meta-analysis of randomized controlled trials. Clinics, 2011, 66, 1923-8.	0.6	17
146	Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 189-192.	0.9	16
147	Risk of Ischemic Stroke after Intracranial Hemorrhage in Patients with Atrial Fibrillation. PLoS ONE, 2015, 10, e0145579.	1.1	16
148	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Europace, 2017, 19, 1630-1636.	0.7	16
149	Evaluating the feasibility of conducting a trial using a patient decision aid in implantable cardioverter defibrillator candidates: a randomized controlled feasibility trial. Pilot and Feasibility Studies, 2017, 3, 49.	0.5	16
150	Right ventricular apical pacing: a necessary evil?. Current Opinion in Cardiology, 2007, 22, 33-38.	0.8	15
151	Periprocedural Management of Oral Anticoagulation in Patients With Atrial Fibrillation: Approach in the Era of New Oral Anticoagulants. Canadian Journal of Cardiology, 2013, 29, S54-S59.	0.8	15
152	The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C-CUSP ED). Annals of Emergency Medicine, 2019, 73, 382-392.	0.3	15
153	Life and Death after ICD Implantation. New England Journal of Medicine, 2008, 359, 1058-1059.	13.9	14
154	Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group. International Journal of Cardiology, 2019, 296, 65-70.	0.8	14
155	Is Defibrillation Testing Necessary for Implantable Transvenous Defibrillators?. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 347-351.	2.1	13
156	Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) followâ€up cohort study. Clinical Cardiology, 2018, 41, 1273-1280.	0.7	13
157	Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. European Heart Journal, 2019, 40, 3026-3032.	1.0	13
158	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. Europace, 2020, 22, 870-877.	0.7	13
159	Newâ€Onset Perioperative Atrial Fibrillation After Coronary Artery Bypass Grafting and Longâ€Term Risk of Adverse Events: An Analysis From the CORONARY Trial. Journal of the American Heart Association, 2021, 10, e020426.	1.6	13
160	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. Europace, 2022, , .	0.7	13
161	Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. Heart Rhythm, 2016, 13, 504-510.	0.3	12
162	The Evolving Role of Stroke Prediction Schemes for Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2013, 29, 1173-1180.	0.8	11

#	Article	lF	CITATIONS
163	Prospective study of tricuspid valve regurgitation associated with permanent leads in patients undergoing cardiac rhythm device implantation: Background, rationale, and design. Global Cardiology Science & Practice, 2015, 2015, 41.	0.3	11
164	Long-term right ventricular implantable cardioverter-defibrillator lead performance in arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2016, 13, 1964-1970.	0.3	11
165	Implantable cardioverter–defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. Heart Rhythm, 2018, 15, 386-392.	0.3	11
166	Left atrial appendage isolation in atrial fibrillation catheter ablation: A metaâ€analysis. Journal of Arrhythmia, 2018, 34, 478-484.	0.5	11
167	Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. Circulation: Heart Failure, 2021, 14, e008548.	1.6	11
168	The Guideline-Policy Gap in Direct-Acting Oral Anticoagulants Usage in Atrial Fibrillation: Evidence, Practice, and Public Policy Considerations. Canadian Journal of Cardiology, 2018, 34, 1412-1425.	0.8	10
169	Screening for undiagnosed atrial fibrillation. Expert Review of Cardiovascular Therapy, 2018, 16, 591-598.	0.6	10
170	Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace, 2019, 22, 47-57.	0.7	10
171	Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial. International Journal of Cardiology, 2019, 288, 87-93.	0.8	10
172	Wearable and implantable diagnostic monitors in early assessment of atrial tachyarrhythmia burden. Europace, 2019, 21, 377-382.	0.7	10
173	Outcomes and Safety of Fluoroless Catheter Ablation for Atrial Fibrillation. CJC Open, 2021, 3, 303-310.	0.7	10
174	Variant Reinterpretation in Survivors of Cardiac Arrest With Preserved Ejection Fraction (the Cardiac) Tj ETQq0 0 Laboratories. Circulation Genomic and Precision Medicine, 2021, 14, e003235.	0 rgBT /0 [,] 1.6	verlock 10 Tf 10
175	New-Onset Atrial Fibrillation After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2022, 15, 603-613.	1.1	10
176	Stroke prevention in patients with atrial fibrillation: The diagnosis and management of hypertension by specialists. Canadian Journal of Cardiology, 2006, 22, 485-488.	0.8	9
177	Troponin Elevation in Patients With Supraventricular Tachycardia: What Does It Mean?. Canadian Journal of Cardiology, 2011, 27, 110-111.	0.8	9
178	Device Surgery without Interruption of Anticoagulation. New England Journal of Medicine, 2013, 369, 1570-1572.	13.9	9
179	The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring. European Heart Journal, 2015, 36, 1640-1642.	1.0	9
180	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American Heart Journal, 2018, 199, 51-58.	1.2	9

#	Article	IF	CITATIONS
181	Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation. CJC Open, 2021, 3, 1482-1489.	0.7	9
182	The effect of atrial-based pacing on exercise capacity as measured by the 6-minute walk test: A substudy of the Canadian Trial of Physiological Pacing (CTOPP). Heart Rhythm, 2007, 4, 1024-1028.	0.3	8
183	New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. Advances in Therapy, 2009, 26, 1058-1071.	1.3	8
184	How to Manage a High Defibrillation Threshold in ICD Patients: and Does it Really Matter?. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 497-505.	0.4	8
185	The New Canadian Cardiovascular Society Algorithm for Antithrombotic Therapy of Atrial Fibrillation Is Appropriately Based on Current Epidemiologic Data. Canadian Journal of Cardiology, 2015, 31, 20-23.	0.8	8
186	Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal, 2019, 210, 29-38.	1,2	8
187	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Catheter Ablation or Antiarrhythmic Drug Therapy: A Systematic Review and Meta-analysis. CJC Open, 2020, 2, 286-295.	0.7	8
188	Associations of symptoms and quality of life with outcomes in patients with atrial fibrillation. Heart, 2020, 106, 1847-1852.	1.2	8
189	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. Thrombosis and Haemostasis, 2021, 121, 518-528.	1.8	8
190	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardiovascular Research, 2022, 118, 295-304.	1.8	8
191	Single-dose oral anti-arrhythmic drugs for cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. Europace, 2021, 23, 1200-1210.	0.7	8
192	Reverse atrial electrical remodelling following atrial defibrillation as determined by signal-averaged ECG. Canadian Journal of Cardiology, 2004, 20, 311-5.	0.8	8
193	Safety of Urgent Cardioversion for Patients With Recent-Onset Atrial Fibrillation and Flutter. Canadian Journal of Cardiology, 2015, 31, 239-241.	0.8	7
194	Apical versus Nonâ€Apical Lead: Is ICD Lead Position Important for Successful Defibrillation?. Journal of Cardiovascular Electrophysiology, 2016, 27, 581-586.	0.8	7
195	Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeons. Europace, 2019, 21, 445-450.	0.7	7
196	Continued versus interrupted direct oral anticoagulation for cardiac electronic device implantation: A systematic review. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1373-1381.	0.5	7
197	Atrial Arrhythmias in Clinically Manifest Cardiac Sarcoidosis: Incidence, Burden, Predictors, and Outcomes. Journal of the American Heart Association, 2020, 9, e017086.	1.6	7
198	Modifiable risk factors predict incident atrial fibrillation and heart failure. Open Heart, 2020, 7, e001092.	0.9	7

#	Article	IF	Citations
199	Remote-only monitoring for patients with cardiac implantable electronic devices: a before-and-after pilot study. CMAJ Open, 2021, 9, E53-E61.	1.1	7
200	The Optimal Timing of Primary Prevention Implantable Cardioverter-Defibrillator Referral in the Rapidly Changing Medical Landscape. Canadian Journal of Cardiology, 2021, 37, 644-654.	0.8	7
201	Association Between Perioperative Atrial Fibrillation and Long-term Risks of Stroke and Death in Noncardiac Surgery: Systematic Review and Meta-analysis. CJC Open, 2021, 3, 666-674.	0.7	7
202	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. Europace, 2021, 23, 748-756.	0.7	7
203	Pro: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation― Thrombosis and Haemostasis, 2009, 102, 912-913.	1.8	6
204	Gastroesophageal reflux and atrial fibrillation: is there any correlation?. Expert Review of Cardiovascular Therapy, 2012, 10, 317-322.	0.6	6
205	Cardiac implantable electronic device infections: From recognizing risk to prevention. Heart Rhythm, 2017, 14, 846-847.	0.3	6
206	The RACE to Treat Atrial Fibrillation in the Emergency Department. New England Journal of Medicine, 2019, 380, 1578-1579.	13.9	6
207	Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. Canadian Journal of Cardiology, 2021, 37, 803-809.	0.8	6
208	Device-detected atrial tachyarrhythmias: what do we know?. Europace, 2012, 14, 157-158.	0.7	5
209	Double twiddle trouble, a new variant of twiddler syndrome. Journal of Arrhythmia, 2016, 32, 236-237.	0.5	5
210	Unconventional warfare: Successful ablation of ventricular tachycardia by direct ventricular puncture in a patient with double mechanical heart valves. HeartRhythm Case Reports, 2017, 3, 599-603.	0.2	5
211	Comparison of health-related quality of life in patients with atrial fibrillation treated with catheter ablation or antiarrhythmic drug therapy: a systematic review and meta-analysis protocol. BMJ Open, 2017, 7, e017577.	0.8	5
212	ST segment depression on 24-hour electrocardiography predicts incident atrial fibrillation in two population-based cohorts. Europace, 2018, 20, 429-434.	0.7	5
213	Although non-stroke outcomes are more common, stroke risk scores can be used for prediction in patients with atrial fibrillation. International Journal of Cardiology, 2018, 269, 145-151.	0.8	5
214	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Europace, 2019, 21, 1023-1030.	0.7	5
215	Effectiveness of single―vs dual oil implantable defibrillator leads: An observational analysis from the SIMPLE study. Journal of Cardiovascular Electrophysiology, 2019, 30, 1078-1085.	0.8	5
216	Detection of atrial fibrillation in asymptomatic at-risk individuals. International Journal of Cardiology, 2021, 334, 55-57.	0.8	5

#	Article	IF	CITATIONS
217	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the <i>ADRB1</i> Arg389Arg Genotype. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009591.	2.1	5
218	Registry on the evaluation of syncope assessment strategy in the emergency room (RESASTER study). Heart Rhythm, 2005, 2, S265-S266.	0.3	4
219	Epsilon Waves During Ventricular Tachycardia in a Case of Arrhythmogenic Right Ventricular Dysplasia. Circulation, 2010, 122, 1752-1755.	1.6	4
220	Successful Implant of a Subcutaneous ICD System in a Patient with an Ipsilateral Epicardial Pacemaker. Indian Pacing and Electrophysiology Journal, 2015, 15, 62-64.	0.3	4
221	"I don't know exactly what you're referring to": the challenge of values elicitation in decision making for implantable cardioverter-defibrillators. Patient Preference and Adherence, 2018, Volume 12, 1947-1954.	0.8	4
222	Differences in Healthcare Use Between Patients With Persistent and Paroxysmal Atrial Fibrillation Undergoing Catheterâ€Based Atrial Fibrillation Ablation: A Populationâ€Based Cohort Study From Ontario, Canada. Journal of the American Heart Association, 2021, 10, e016071.	1.6	4
223	LVSâ€HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a Worldâ€Wide Registry. Journal of the American Heart Association, 2021, 10, e017735.	1.6	4
224	Bad lead? Good lead? What should we believe?. Heart Rhythm, 2009, 6, 210-211.	0.3	3
225	A rare cause of implantable cardioverter-defibrillator failure: Short-circuiting via an unused pace/sense lead. Heart Rhythm, 2010, 7, 1630-1631.	0.3	3
226	Does catheter ablation for atrial fibrillation increase or reduce neurological insult?. Current Opinion in Cardiology, 2012, 27, 36-40.	0.8	3
227	The left atrium: An overlooked prognostic tool. European Journal of Preventive Cardiology, 2017, 24, 389-391.	0.8	3
228	Subclinical atrial fibrillation: The significance of progression to longer episodes. Heart Rhythm, 2018, 15, 384-385.	0.3	3
229	Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 154-155.	1.2	3
230	Canadian Nephrologist Views Regarding Stroke and Systemic Embolism Prevention in Dialysis Patients With Nonvalvular Atrial Fibrillation: A Survey. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811882194.	0.6	3
231	Atrial fibrillation and stroke: chicken or egg? Does it really matter?. Europace, 2020, 22, 509-510.	0.7	3
232	Canadian Heart Rhythm Society Task Force Report on Physician Training and Maintenance of Competency for Cardiovascular Implantable Electronic Device Therapies: Executive Summary. Canadian Journal of Cardiology, 2021, 37, 1857-1860.	0.8	3
233	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS 2 Score: Insights From the BRAIN-AF Trial. Circulation: Arrhythmia and Electrophysiology, 2022, , CIRCEP121010462.	2.1	3
234	Use of Anticoagulation Therapy in Patients With Perioperative Atrial Fibrillation After Cardiac Surgery: AÂSystematic Review and Meta-analysis. CJC Open, 2022, 4, 840-847.	0.7	3

#	Article	IF	CITATIONS
235	Trifecta or Triple Threat? The Challenge of Post-PCI Management in Patients Receiving Chronic Oral Anticoagulant Therapy. Canadian Journal of Cardiology, 2013, 29, 136-138.	0.8	2
236	Response to Letters Regarding Article, "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial― Circulation, 2013, 127, e506.	1.6	2
237	Oral Anticoagulant Use in Patients With Chronic Kidney Disease: How to Choose, and the Importance of Empiric Human Data. Canadian Journal of Cardiology, 2014, 30, 853-854.	0.8	2
238	The Role of Defibrillation Testing. Cardiac Electrophysiology Clinics, 2015, 7, 539-546.	0.7	2
239	Letter by Hess et al Regarding Article, "How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoringပ Circulation, 2016, 134, e28-9.	1.6	2
240	The winding path towards rationale anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation. European Heart Journal, 2018, 39, 474-476.	1.0	2
241	Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. Canadian Journal of Cardiology, 2018, 34, 808-811.	0.8	2
242	Rate, Time Course, and Predictors of Implantable Cardioverter Defibrillator Infections: An Analysis From the SIMPLE Trial. CJC Open, 2020, 2, 354-359.	0.7	2
243	Prospective Long-term Follow-up of Silicone-polyurethane - insulated Implantable Cardioverter Defibrillator Leads. Heart Rhythm O2, 2021, 3, 57-64.	0.6	2
244	Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2022, 38, 1434-1441.	0.8	2
245	At What Age Does Stroke Risk Increase in Patients With Atrial Fibrillation? Does It Depend on Where You Live?. Canadian Journal of Cardiology, 2016, 32, 1364-1365.	0.8	1
246	Harder Roads to Trek? Paradoxical Slowing of an Atrioventricular Reentrant Tachycardia With Contralateral Bundle Branch Block. Journal of Cardiovascular Electrophysiology, 2017, 28, 455-457.	0.8	1
247	PREDICTORS OF ANTICOAGULANT PRESCRIPTION IN PATIENTS WITH ATRIAL FIBRILLATION IN NORTH AMERICA: THE GLORIA-AF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 413.	1.2	1
248	What Do Implanted Cardiac Monitors Reveal About Atrial Fibrillation?. JAMA Cardiology, 2017, 2, 1128.	3.0	1
249	Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients ≥75 Years Versus <75 Years Receiving Cardiac Resynchronization Therapy. American Journal of Cardiology, 2018, 121, 975-980.	0.7	1
250	Late Stroke After Coronary Artery Bypass Grafting. JAMA Cardiology, 2018, 3, 425.	3.0	1
251	Incident Atrial Fibrillation and Stroke in Patients With Atrial Flutter. Canadian Journal of Cardiology, 2018, 34, 696-697.	0.8	1
252	Defibrillation testing and clinical outcomes after implantable cardioverter–defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial. Heart Rhythm, 2019, 16, 83-90.	0.3	1

#	Article	IF	Citations
253	Pre-Screening for Atrial Fibrillation Using the Electronic Health Record. JACC: Clinical Electrophysiology, 2019, 5, 1342-1343.	1.3	1
254	Shared Decision-Making for Anticoagulation in Atrial Fibrillation: Do Physicians Really Listen?. Canadian Journal of Cardiology, 2020, 36, 459-461.	0.8	1
255	Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008655.	2.1	1
256	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. PLoS ONE, 2020, 15, e0226259.	1.1	1
257	Is Screening for Atrial Fibrillation and Its Risk Factors Useful and Cost-Effective?. Cardiac Electrophysiology Clinics, 2021, 13, 235-241.	0.7	1
258	Systematic review of treatment gaps in oral anticoagulant use in atrial fibrillation. Thrombosis Update, 2021, 4, 100053.	0.4	1
259	Contralateral Pneumothorax in Left Sided CRT Device Implantation. Indian Pacing and Electrophysiology Journal, 2011, 11, 16-9.	0.3	1
260	A Case of Longâ€RP Tachycardia: What is the Mechanism?. Journal of Cardiovascular Electrophysiology, 2009, 20, 702-704.	0.8	0
261	Entrainment of supraventricular tachycardia: What is the mechanism?. Heart Rhythm, 2011, 8, 1809-1811.	0.3	0
262	Reply to the Editorâ€"Shocks and Mortality versus Pacing and Mortality. Heart Rhythm, 2013, 10, e9-e10.	0.3	0
263	Defibrillator discharges in a young patient: What is the underlying arrhythmia?. Heart Rhythm, 2014, 11, 2202-2205.	0.3	0
264	Response to Letter Regarding Article, "Left Atrial Appendage Occlusion Debate Revisited― Circulation, 2015, 132, e230.	1.6	0
265	Complications of defibrillation testing. Herzschrittmachertherapie Und Elektrophysiologie, 2015, 26, 320-323.	0.3	0
266	Response to Letter Regarding Article "Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events― Circulation, 2015, 131, e337-8.	1.6	0
267	Resetting of a Supraventricular Tachycardia by a Ventricular Premature Beat. What is the Mechanism?. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1005-1008.	0.5	0
268	Consistent Inconsistency? Is There Pacemaker Malfunction?. Journal of Cardiovascular Electrophysiology, 2016, 27, 131-133.	0.8	0
269	Response by Parkash et al to Letters Regarding Article, "Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])― Circulation, 2017, 136, 1271-1272.	1.6	0
270	Limitations of Administrative Data for Examining Secondary Atrial Fibrillation. JACC: Clinical Electrophysiology, 2018, 4, 561-562.	1.3	0

#	Article	IF	CITATIONS
271	Sedation strategies for defibrillation threshold testing: safety outcomes with anaesthesiologist compared to proceduralist-directed sedation: an analysis from the SIMPLE study. Europace, 2018, 20, 1798-1803.	0.7	0
272	Clinical Outcomes in AtrialÂFibrillationÂResearch. JACC: Clinical Electrophysiology, 2019, 5, 606-607.	1.3	0
273	FEASIBILITY AND EFFECT OF REMOTE AMBULATORY HEART RHYTHM MONITORING PRE AND POST TAVI. Journal of the American College of Cardiology, 2019, 73, 2029.	1.2	0
274	Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment—Reply. JAMA Neurology, 2020, 77, 134.	4.5	0
275	Implantable Cardioverter-Defibrillator and Lipomas: A Case-Series. Plastic Surgery Case Studies, 2021, 7, 2513826X2110084.	0.1	0
276	Who is at risk of atrial fibrillation?. Heart Rhythm, 2021, 18, 853-854.	0.3	0
277	Antidiabetic drugs for preventing atrial fibrillation: A new revolution?. Heart Rhythm, 2021, 18, 1097.	0.3	0
278	OCEAN Trial Update. American Heart Journal, 2021, , .	1.2	0
279	Reply. Journal of the American College of Cardiology, 2021, 78, e91-e92.	1.2	0
280	Denervação simpática renal: usando uma velha ferramenta para um novo trabalho?. Revista Brasileira De Cardiologia Invasiva, 2013, 21, 3-4.	0.1	0
281	Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study. Open Cardiovascular Medicine Journal, 2014, 8, 94-101.	0.6	0
282	Clinical outcomes in patients with systolic heart failure. Are atrial high rate episodes a common marker of disease progression?. International Journal of Cardiology, 2020, 316, 184-185.	0.8	0
283	444â€fEpidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: a systematic review and meta-regression. European Heart Journal Supplements, 2021, 23, .	0.0	0
284	Previous history of hyperthyroidism in emergency department patients with atrial fibrillation does not increase the risk of thromboembolism and death Annals of the Academy of Medicine, Singapore, 2022, 51, 250-252.	0.2	0